A Double-Blind, Randomized, Placebo-Controlled, Ascending Single-Dose, Phase I Trial of the Anti-Orthopoxvirus Compound SIGA-246 in Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 03 Feb 2017
At a glance
- Drugs Tecovirimat (Primary)
- Indications Orthopoxvirus infections
- Focus Adverse reactions; Pharmacokinetics
- 13 Apr 2008 Results presented at International Conference on Antiviral Research in April 2008.
- 02 Jun 2006 New trial record.